241 related articles for article (PubMed ID: 24463451)
1. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
Orwoll ES; Shapiro J; Veith S; Wang Y; Lapidus J; Vanek C; Reeder JL; Keaveny TM; Lee DC; Mullins MA; Nagamani SC; Lee B
J Clin Invest; 2014 Feb; 124(2):491-8. PubMed ID: 24463451
[TBL] [Abstract][Full Text] [Related]
2. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
[TBL] [Abstract][Full Text] [Related]
4. Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy.
Nicol L; Wang Y; Smith R; Sloan J; Nagamani SC; Shapiro J; Lee B; Orwoll E
J Bone Miner Res; 2018 Feb; 33(2):307-315. PubMed ID: 29044725
[TBL] [Abstract][Full Text] [Related]
5. Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.
Hald JD; Keerie C; Weir CJ; Javaid MK; Lam W; Osborne P; Walsh J; Langdahl BL; Ralston SH
BMJ Open; 2023 Nov; 13(11):e078164. PubMed ID: 37993151
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
9. Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.
Takada J; Yoshimura T; Uzawa T
J Bone Miner Metab; 2021 May; 39(3):484-493. PubMed ID: 33389132
[TBL] [Abstract][Full Text] [Related]
10. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
11. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.
Cohen A; Shiau S; Nair N; Recker RR; Lappe JM; Dempster DW; Nickolas TL; Zhou H; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Williams JM; McMahon DJ; Stubby J; Shane E
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3540-56. PubMed ID: 32876328
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.
Paggiosi MA; Yang L; Blackwell D; Walsh JS; McCloskey E; Peel N; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1367-1378. PubMed ID: 29520607
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
15. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
17. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
18. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
Chen FP; Fu TS; Lin YC; Sung CM; Huang MH; Lin YJ
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
[TBL] [Abstract][Full Text] [Related]
19. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
20. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
